[~116H7900]

			(Original Signature of Member)
117TH CONGRESS	TT	D	

1 1st Session

## П. К.

To amend the National Organ Transplant Act to clarify the definition of valuable consideration, to clarify that pilot programs that honor and promote organ donation do not violate that Act, and for other purposes.

## IN THE HOUSE OF REPRESENTATIVES

Mr. Cartwright	introduced the	following bill;	which wa	s referred t	to the
Comm	nittee on				

## A BILL

To amend the National Organ Transplant Act to clarify the definition of valuable consideration, to clarify that pilot programs that honor and promote organ donation do not violate that Act, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- tives of the United States of America in Congress assembled,
- SECTION 1. SHORT TITLE.
- This Act may be cited as the "Organ Donation Clari-4
- fication Act of 2021".
- SEC. 2. FINDINGS. 6
- 7 Congress finds the following:

(1) As of March 2021, 108,000 people await an
organ transplant, with 91,000 of those people wait-
ing for a kidney, and average wait times are ap-
proaching five years for a kidney, with over one-and-
a-half times as many people being added to the wait-
ing lists as getting a transplant.
(2) Of the nearly three million Americans who
die annually, under 30,000, representing about one
percent of all deaths each year, possess major or-
gans healthy enough for transplanting.
(3) On average, 17 people a day died while
waiting for an organ in 2020, with the majority of
those people waiting for a kidney.
(4) In 2020, approximately 3,800 people were
removed from kidney waiting lists and approximately
1,600 from liver, heart, and lungs waiting lists be-
cause they became permanently too sick to receive a
transplant.
(5) Over 75 percent of dialysis patients are not
employed because dialysis requires multiple treat-
ments per week which last several hours and leave
patients drained, thus creating a huge financial bur-
den on the patients, their families, and the govern-
ment; moreover, lost tax revenue from these individ-

uals is not included in the cost estimates above.

25

t, and
,
much
on av-
ves on
ill in-
iduals
dicare
Pro-
0,000
s that
o has
n less
aver-
ar pe-
ayers.
trans-
e de-
than
mates
on the
r des-

1	perate patients facing an alternative of death, how-
2	ever recipients often receive infected kidneys and
3	suffer poor health outcomes and donors are often
4	victimized.
5	(12) Present policy on domestic donation has
6	never been subject to studies or pilots to determine
7	effectiveness in increasing the availability of donated
8	organs and the effectiveness of safeguards that pre-
9	vent coercion or exploitation, precludes all but altru-
10	istic donation, prohibiting any form of incentive or
11	benefit for donors.
12	(13) In 2010, Israel implemented sweeping
13	changes to its national organ donation program in-
14	cluding reducing financial burdens on donors, giving
15	future transplantation priority to registered organ
16	donors and their families, and promoting donation
17	by reimbursing the donor's medical costs, 40 days of
18	lost wages, and five years of medical and life insur-
19	ance costs, and as a result saw organ donation ap-
20	proximately triple over a 10-year period.
21	(14) Experts are arriving at a consensus that
22	trials are necessary to find new methods of pro-
23	moting additional organ donation which will save
24	lives and reduce organ trafficking.

1	SEC. 3. CLARIFICATION OF CERTAIN PROVISIONS OF THE
2	NATIONAL ORGAN TRANSPLANT ACT.
3	(a) Relation to Other Laws.—Section 301 of the
4	National Organ Transplant Act (42 U.S.C. 274e) is
5	amended by adding at the end the following:
6	"(d) Relation to Other Laws.—
7	"(1) Governments encouraging organ do-
8	NATION.—This section shall not—
9	"(A) apply to actions taken by the Govern-
10	ment of the United States or any State, terri-
11	tory, tribe, or local government of the United
12	States to carry out a covered pilot program; or
13	"(B) prohibit acceptance of any noncash
14	benefits provided by the pilot program under
15	subparagraph (A).
16	"(2) No prohibition on other benefits
17	PROGRAMS.—Nothing in this subsection shall be con-
18	strued to prohibit actions, other than actions de-
19	scribed in this section, taken by any State, territory,
20	tribe, or unit of local government in the United
21	States to provide benefits for human organ donation.
22	"(3) COVERED PILOT PROGRAM.—For purposes
23	of this subsection—
24	"(A) the term 'covered pilot program'
25	means a pilot program approved by the Sec-
26	retary of Health and Human Services, subject

1	to an ethical review board process, with a term
2	of not more than 5 fiscal years, for the purpose
3	of measuring the effect of removing disincen-
4	tives or providing a noncash benefit that may
5	increase the organ pool. Distributions of organs
6	from deceased donors under the pilot program
7	shall be conducted only through the Organ Pro-
8	curement and Transplantation Network at a
9	transplant center approved by the United Net-
10	work for Organ Sharing or any other entity
11	designated by the Secretary of Health and
12	Human Services; and
13	"(B) the term 'noncash benefit' means any
14	benefit or thing of value received by an organ
15	donor that is impossible to sell, trade, or other-
16	wise transfer to another individual.".
17	(b) Valuable Consideration.—Section 301(c)(2)
18	of the National Organ Transplant Act (42 U.S.C.
19	274e(c)(2)) is amended to read as follows:
20	"(2) The term 'valuable consideration' does not
21	include the following:
22	"(A) Reasonable payments associated with
23	the removal, transportation, implantation, proc-
24	essing, preservation, quality control, and stor-
25	age of a human organ.

1	"(B) Reimbursement for travel, lodging,
2	food during travel, and other logistical expenses
3	related to donation.
4	"(C) Provision of advanced payments or
5	reimbursement for dependent care needs for
6	pre-transplant appointments in addition to dur-
7	ing the period of donation and post-transplant
8	follow-up care related to the donation for up to
9	a 10-year period.
10	"(D) Reimbursement for lost wages related
11	to donation.
12	"(E) Medical expenses related to donation
13	and all related follow-up care including prevent-
14	ative follow-up care and medication for up to a
15	10-year period.
16	"(F) Paperwork or legal costs related to
17	donation.
18	"(G) Any term life insurance policy against
19	the risk of death or disability as a result of do-
20	nating an organ or the longer-term health ef-
21	fects of having donated an organ, that—
22	"(i) in the case of a life insurance pol-
23	icy, provides for payments in amounts less
24	than \$2,000,000, adjusted annually for in-
25	flation; and

8

1	"(ii) in the case of a disability insur-
2	ance policy, provides for payments equal to
3	or less than the reasonable earnings expec-
4	tations of the donor.".